Compared with triple-negative (ie, MSI-negative, KRAS and BRAF wild-type) cancers, MSI-negative tumours with KRAS (HR 1·35 [95% CI 1·11–1·64]; p=0·003) or BRAF (2·02 [1·47–2·76]; 1·20 × 10−5) mutations were associated with worse prognosis (table 4, figure 2). This evidence concerns the gene BRAF and cancer.